Align Tech Faces Slowing Growth, Potential Headwinds, Morgan Stanley Says In Downgrade
Henry Schein, Patterson Companies Downgraded On Amazon Fears
Dentsply Sirona Is At An Attractive Entry Point For Investors Seeking Play On Structural Growth In Med-Tech
Even After Dipping Under $21, Morgan Stanley Says Myriad Genetics Is Not Cheap
Steve Beuchaw Recent News
Morgan Stanley Sees Illumina Trading At Too High A Premium To Its Peers
Cepheid Margin Expansion Unlikely To Morgan Stanley, Stays On Sidelines
Agilent's FY17 Outlook Weaker Than Expected, But Looks Beatable, Morgan Stanley Says
Morgan Stanley Downgrades Dentsply, Says 'Time For A Breather'
A Dentist's Pair Trade: Buy Dentsply, Sell Sirona Dental
Morgan Stanley Neutral On Natera, Starts At Equal-Weight
Morgan Stanley Reiterates Overweight, Raises PT On NanoString Technologies On Increased Visibility
Morgan Stanley Reiterates Equal-Weight, Lowers PT On Veracyte As Expectations Are Now Better Calibrated
Morgan Stanley Goes Over Accuray's Pros And Cons
UPDATE: Morgan Stanley Initiates Coverage On Myriad Genetics As Survey Points To Greater Share Loss
UPDATE: Morgan Stanley Reiterates On Agilent Technologies On Balanced Risk-Reward
UPDATE: Morgan Stanley Reiterates On Varian Medical Systems, Inc. As Reimbursement Change Is Coming for 2015
Morgan Stanley Has Low Expectations For Sirona Dental Systems
UPDATE: Morgan Stanley Reiterates On Varian Medical Systems On Mid-Year Updates
Morgan Stanley Believes Upside for DENTSPLY International Requires Macro Acceleration or FX Reversal
UPDATE: Morgan Stanley Reiterates on Sirona Dental Systems on EPS Acceleration Ahead
Morgan Stanley Maintains on Varian Medical Systems